Collect Your Medical Records: Gather all relevant documents, such as pharmacy receipts, medical records, lab results and discharge summaries
On 24 November 2025, Novo Nordisk reported that oral semaglutide had failed to slow Alzheimers disease in the EVOKE and EVOKE+ trials, which together enrolled 3,808 participants and stand as the largest evaluation of this drug class in any neurodegenerative condition [1]
The PCAC has warned that BPC-157 products from unreputable suppliers may carry peptide fragments, leftover solvents, and other impurities that were never properly identified or removed
DOI: 10.3390/life11010003 [Google Scholar] Damerau A, Rosenow E, Alkhoury D, Buttgereit F, Gaber T